The first bevacizumab bio similar drug in China, Qilu pharmaceutical can be approved for marketing

On December 9, the State Drug Administration approved the application for listing and registration of bevacizumab injection (trade name: antake) developed by Qilu Pharmaceutical Co., Ltd It is the first biologically similar bevacizumab approved in China It is mainly used for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer Bevacizumab is a humanized monoclonal antibody IgG1 prepared by recombinant DNA technology It can inhibit the binding of VEGF and its receptor, block the signal transduction pathway of angiogenesis, and inhibit the growth of tumor cells by binding with VEGF Bevacizumab, as one of the important anti-tumor angiogenesis drugs, has been used in the treatment of many kinds of malignant tumors The approved bevacizumab injection was declared by Qilu Pharmaceutical Co., Ltd., which is the first domestic product developed and applied for production by the way of biological similar drugs with the original bevacizumab as the reference drug, and obtained the special support of national major new drug development The State Drug Administration approved the listing of the product according to the priority review and approval procedure The approval of this product will improve the accessibility of this kind of drugs and provide a new choice for the treatment of patients in China Xi If you are involved in the work content, copyright and other questions, please contact the official account message We will delete the content at the first time.